Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
Saved in:
| Title: | Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern? |
|---|---|
| Authors: | Milder TY; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine & Health, University of New South Wales, Sydney, Australia.; Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, Australia.; School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia., Lin J; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine & Health, University of New South Wales, Sydney, Australia., Pearson SA; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine & Health, University of New South Wales, Sydney, Australia., de Oliveira Costa J; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine & Health, University of New South Wales, Sydney, Australia., Neuen BL; The George Institute for Global Health, University of New South Wales, Sydney, Australia.; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.; Faculty of Medicine and Health, The University of Sydney, Australia., Pollock C; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.; Faculty of Medicine and Health, The University of Sydney, Australia., Jun M; The George Institute for Global Health, University of New South Wales, Sydney, Australia., Greenfield JR; Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, Australia.; School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia.; Department of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, Australia., Day RO; School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia.; Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia., Stocker SL; School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia.; Faculty of Medicine and Health, The University of Sydney, Australia.; Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia., Brieger D; Faculty of Medicine and Health, The University of Sydney, Australia.; Department of Cardiology, Concord Repatriation General Hospital, Sydney, Australia., Falster MO; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine & Health, University of New South Wales, Sydney, Australia. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Feb; Vol. 27 (2), pp. 997-1000. Date of Electronic Publication: 2024 Nov 07. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1463-1326 |
|---|---|
| DOI: | 10.1111/dom.16061 |
